Clinical data spotlight at PALTC26

Neurocrine Biosciences (NBIX) used the PALTC26 conference in Anaheim to spotlight new guidance and data on tardive dyskinesia care in older adults, centering on its INGREZZA treatment and real world patient reported outcomes.

At a share price of US$131.60, Neurocrine Biosciences has seen a 1 year total shareholder return of about 28%, even as its 90 day share price return of roughly 6% suggests some momentum has cooled following recent gains and news flow around INGREZZA.

If this type of specialist healthcare story interests you, it can be worth widening your search beyond a single name to see what else is emerging in AI driven drug development, including 37 healthcare AI stocks.

With shares at US$131.60, a 1 year total return near 28%, solid recent revenue and net income growth, and some analyst targets sitting higher, investors now face a key question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 26.1% Undervalued

With Neurocrine Biosciences last closing at $131.60 against a narrative fair value of $178.04, the gap between price and modeled worth is hard to ignore.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides) and a strong preclinical pipeline allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Want to see what earnings trajectory and margin profile sit behind that valuation gap? The most followed narrative leans on specific growth, profitability and discount rate assumptions that could surprise you.

Result: Fair Value of $178.04 (UNDERVALUED)

However, investors still need to weigh pricing pressure on INGREZZA and growing payer scrutiny, along with concentration risk if INGREZZA or CRENESSITY underperform expectations.

Another View: Multiples Point To A Richer Price Tag

The narrative fair value of $178.04 suggests upside, but the current P/E of 27.6x tells a different story. That is above the peer average of 21x, the US Biotechs industry at 14.9x, and the fair ratio of 22x. This implies limited room for error if growth or margins disappoint.

For a closer look at how this pricing gap could matter for risk and return, and how it might evolve over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seeing mixed signals on value and risks so far? Take a closer look at the underlying drivers, and move quickly to form your own view with 4 key rewards

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals even better, so consider putting a few more high quality ideas on your radar.

• Target robust fundamentals and resilience by scanning companies in the solid balance sheet and fundamentals stocks screener (39 results). These can help anchor the more volatile parts of your portfolio.
• Hunt for quality at a price that looks appealing by reviewing the 62 high quality undervalued stocks and seeing which names line up with your risk comfort and time horizon.
• Add potential income streams by focusing on the 12 dividend fortresses and shortlisting businesses that offer yields you feel comfortable relying on over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.